Free Trial

American Trust Invests $757,000 in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

IDEXX Laboratories logo with Medical background

American Trust purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,499 shares of the company's stock, valued at approximately $757,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Chicago Partners Investment Group LLC lifted its position in IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock valued at $340,000 after acquiring an additional 96 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of IDEXX Laboratories by 13.8% in the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock valued at $5,825,000 after purchasing an additional 1,453 shares in the last quarter. National Pension Service boosted its position in shares of IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company's stock valued at $93,957,000 after buying an additional 12,647 shares during the last quarter. EFG Asset Management Americas Corp. grew its holdings in IDEXX Laboratories by 45.3% during the second quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock worth $6,201,000 after buying an additional 3,966 shares in the last quarter. Finally, Larson Financial Group LLC raised its position in IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after buying an additional 2,241 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX traded down $5.08 during trading hours on Friday, hitting $432.10. The stock had a trading volume of 330,704 shares, compared to its average volume of 512,194. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company's fifty day simple moving average is $440.46 and its 200 day simple moving average is $472.39. The stock has a market cap of $35.38 billion, a PE ratio of 42.16, a price-to-earnings-growth ratio of 3.99 and a beta of 1.37. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company's revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the company earned $2.53 earnings per share. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company's stock, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.11% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on IDXX shares. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a report on Thursday, October 10th. JPMorgan Chase & Co. reduced their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a research report on Friday, October 11th. Piper Sandler reissued a "neutral" rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 target price for the company. Finally, StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, November 28th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $539.63.

View Our Latest Analysis on IDEXX Laboratories

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Further Reading

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

→ DeFi Coin on Verge of Breakout! (From Crypto 101 Media) (Ad)

Should you invest $1,000 in IDEXX Laboratories right now?

Before you consider IDEXX Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.

While IDEXX Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?
SoundHound Stock Explodes Again – Is a Major Breakout Coming?
How Fintech Strategy at FinWise Bancorp and CEO Vision Are Driving 78% Gains

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines